Clinical Evidence
Rigorous validation studies demonstrating DeepGAD™'s clinical performance and safety. Our technology has been validated through prospective clinical trials with leading medical institutions.
Prospective Reader Study Results
Study Design & Methodology
Study Population
- • 101 consecutive patients (18-85 years)
- • Indication: Brain MRI with contrast
- • Exclusion: Pregnancy, severe renal impairment
- • Multi-center study (3 academic hospitals)
Imaging Protocol
- • 3T MRI scanners (Siemens, GE, Philips)
- • Standard T1w sequences pre/post contrast
- • 20% GBCA dose (~3ml vs ~15ml standard)
- • DeepGAD™ processing < 2 minutes
Blinded Reader Study
Comprehensive clinical validation conducted by independent expert radiologists
Expert Radiologists
Board-certified neuroradiologists with 5+ years experience
Reading Sessions
Blinded evaluation of full-dose vs AI-enhanced images
Week Interval
Minimum washout period between reading sessions
Evaluation Criteria
Comprehensive assessment framework used by expert radiologists
Image Quality Metrics
Diagnostic Confidence
Key Findings
Non-Inferior Diagnostic Performance
DeepGAD™-enhanced images demonstrated non-inferior diagnostic performance compared to full-dose contrast images across all evaluation criteria.
- • 94% agreement in lesion detection
- • No significant difference in diagnostic confidence
- • Equivalent image quality scores
Safety & Tolerability
No adverse events related to reduced gadolinium dose. All patients tolerated the 20% dose protocol without complications.
- • Zero contrast-related adverse events
- • 100% patient completion rate
- • No protocol deviations
Clinical Impact
Radiologists reported equivalent diagnostic confidence and clinical decision-making capability with AI-enhanced images.
- • 98% would use in clinical practice
- • 95% reported equivalent diagnostic confidence
- • 100% recommended further evaluation
Workflow Integration
Seamless integration with existing PACS systems and minimal impact on radiology workflow.
- • PACS integration ready
- • Processing time: < 2 minutes
- • Real-time processing capability
Quantitative Performance Metrics
SSIM
Structural Similarity Index
PSNR
Peak Signal-to-Noise Ratio
SNR
vs. low-dose acquisition
Vessel Conspicuity
vs. low-dose images
Publications & Presentations
Prospective Clinical Validation of DeepGAD™ for Low-Dose Gadolinium-Enhanced Brain MRI
Radiology (2024) - In Press
First prospective clinical study demonstrating non-inferior diagnostic performance of AI-enhanced low-dose gadolinium brain MRI compared to standard full-dose protocols.
Deep Learning for Gadolinium Dose Reduction in Contrast-Enhanced MRI: A Systematic Review
Journal of Medical Imaging (2024) - Under Review
Comprehensive review of AI approaches for contrast dose reduction, highlighting DeepGAD™'s clinical validation and performance advantages.
RSNA 2024 Scientific Assembly
Oral Presentation - "Clinical Validation of AI-Enhanced Low-Dose Gadolinium Brain MRI"
Presented prospective reader study results to international radiology community at RSNA 2024.
Regulatory Pathway
DeepGAD™ is currently under clinical evaluation and not yet FDA-cleared. We are working with regulatory authorities to establish the appropriate pathway for market authorization.
Clinical Trials
Prospective studies completed
FDA Submission
Pre-submission meeting scheduled
Market Launch
Expected 2025